GSK to acquire RAPT Therapeutics for equity value of $2.2 billion
MLex Summary: London-based GSK has agreed to acquire San Francisco-based RAPT Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients living with inflammatory and immunologic diseases, for an...To view the full article, register now.
Already a subscriber? Click here to view full article